Background Surgery for craniosynostosis is associated with the potential for significant
blood loss. Multiple technologies have been introduced to reduce the volume of blood …

Background: Prevention of blood loss is a chief consideration in plastic and reconstructive
surgery. The antifibrinolytic drugs tranexamic acid and ε-aminocaproic acid have emerged …

Background Antifibrinolytic therapy significantly decreases blood loss and transfusion in
pediatric cranial vault reconstructive surgery; however, concern regarding the side effects …

Background Blood loss is the leading cause of mortality after major craniofacial surgery.
Autologous blood donation, short-term normovolemic hemodilution, and intraoperative …

Background Surgical correction of craniosynostosis in children is associated with substantial
intraoperative bleeding. Intraoperatively administered tranexamic acid (TXA) can lessen …

Introduction Our center previously reported low transfusion rates for craniosynostosis
surgery by two experienced neurosurgeons using standard intraoperative techniques and …

Object Children with craniosynostosis may require cranial vault remodeling to prevent or
relieve elevated intracranial pressure and to correct the underlying craniofacial …

Purpose: Tranexamic acid (TXA) is prescribed for short term management of haemorrhage. It
is also administered prophylatically in surgeries where blood loss is anticipated. Tranexamic …

OBJECTIVE Craniosynostosis surgery is associated with considerable blood loss and need
for transfusion. Considering the lower estimated blood volume (EBV) of children compared …

Background Intraoperative tranexamic acid (TXA) administration has been used to abate
blood loss in a variety of surgical procedures. Several recent studies have supported its …